EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Hydrocortisone in Preterm Infants and School-Age Functional Outcomes

Hydrocortison bei Frühgeborenen und funktionelle Outcomes im Schulalter

Sara B DeMauro, Haresh Kirpalani, Susan Hintz, Kristi L Watterberg, Victoria Watson, Jean Lowe, Seetha Shankaran, Sanjay Chawla, Betty Vohr, Michael E Msall, Carl T D'Angio, Bradley A Yoder und 37 weitere

JAMA Pediatrics · 01.02.2026 · 180 (2) · 134

DOI: 10.1001/jamapediatrics.2025.4801 ↗

Auf einen Blick

In einer Nachbeobachtung der Hydrocortisone for BPD Trial zeigte Hydrocortison bei frühgeborenen, intubierten Kindern keinen Unterschied bei funktioneller Beeinträchtigung im frühen Schulalter gegenüber Placebo.

Fragestellung

Welchen Einfluss hat eine neonatale Hydrocortisonbehandlung auf funktionelle motorische, kognitive, schulische und pulmonale Outcomes im frühen Schulalter?

Methode

Prospektive Langzeit-Kohortenstudie als Follow-up einer randomisierten klinischen Studie an 19 Zentren; randomisiert zu Hydrocortison oder Placebo ab Tag 14 bis 28; Nachuntersuchung zwischen korrigiertem Alter 5 Jahre 0 Monate und 7 Jahre 11 Monate.

Ergebnisse

Primärer Endpunkt bei 545 von 674 berechtigten Kindern. Funktionelle Beeinträchtigung: 71,3 % unter Hydrocortison vs. 73,3 % unter Placebo; adjustiertes relatives Risiko 0,99 (95 %-KI 0,89–1,10). Keine Unterschiede in den Einzelkomponenten.

Schlussfolgerung der Autor:innen

Eine neonatale Hydrocortisonbehandlung bei Frühgeborenen mit hohem BPD-Risiko beeinflusste funktionelle Beeinträchtigung oder deren Komponenten nicht; fast drei Viertel zeigten Beeinträchtigung im Schulalter.

Kernaussagen

  • Funktionelle Beeinträchtigung: 71,3 % vs. 73,3 %
  • Adjustiertes relatives Risiko 0,99 (95 %-KI 0,89–1,10)
  • Keine Unterschiede bei den Einzelkomponenten des primären Endpunkts

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Pediatrics, erschienen am 01.02.2026. Verfasst von Sara B DeMauro und 48 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Hydrocortisone, Bronchopulmonary Dysplasia, Child Development, Anti-Inflammatory Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Bronchopulmonary dysplasia (BPD) is the most common in-hospital morbidity of prematurity, associated with significant long-term medical and neurodevelopmental sequelae and health resource utilization. The Neonatal Research Network (NRN) Hydrocortisone for BPD Trial evaluated the efficacy and safety of hydrocortisone to prevent BPD in high-risk very preterm infants; the impact of hydrocortisone on school-age outcomes in this trial cohort is previously unreported.

Objective

To evaluate the impact of neonatal hydrocortisone treatment on early school-age functional motor, cognitive, academic, and pulmonary outcomes among children who participated in the Hydrocortisone for BPD Trial. Design, Setting, and Participants This prospective long-term cohort study is a follow-up of a randomized clinical trial, the Hydrocortisone for BPD Trial, conducted at 19 centers of the Eunice Kennedy Shriver National Institute of Child Health and Human Development NRN. Participants, enrolled from August 2011 to February 2018, included intubated infants who had been born before 30 weeks’ gestational age and had been mechanically ventilated for at least 7 days by postnatal day 14 to 28. They were eligible for a single, in-person, early school-age visit between corrected age 5 years 0 months and 7 years 11 months, conducted from September 2017 to July 2024. Data analysis was performed from July 2024 to September 2025.

Intervention

Participants were randomized to a 10-day tapering course of hydrocortisone or placebo beginning at 14 to 28 postnatal days. Main Outcomes and Measures Early school-age study visits were performed by certified, masked assessors. The primary outcome of functional impairment was defined as any of the following: cognitive delay, motor delay, academic delay, or poor functional exercise capacity.

Results

The primary outcome was available for 545 of 674 eligible children (80.9%), including 272 children in the hydrocortisone group (152 [55.9%] female; mean [SD] gestational age, 24.9 [1.5] weeks; mean [SD] age at visit, 5.3 [0.6] years) and 273 in the placebo group (108 [39.6%] female; mean [SD] gestational age, 24.8 [1.5] weeks; mean [SD] age at visit, 5.4 [0.6] years). There was no difference in the rate of functional impairment between the hydrocortisone group (194 of 272 children [71.3%]) and the placebo group (200 of 273 children [73.3%]) (adjusted relative risk, 0.99; 95% CI, 0.89-1.10), nor were there differences in the rates of the individual components. Motor delay was the most common impairment (308 of 510 children [60.4%]), followed by poor functional exercise capacity (175 of 484 children [36.2%]). Conclusions and Relevance In this study, neonatal hydrocortisone treatment of preterm infants with high risk for BPD did not impact functional impairment or its components; nearly three-quarters of the children demonstrated functional impairment at school age. Trial Registration ClinicalTrials.gov Identifier: NCT01353313

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrocortisoneBronchopulmonary DysplasiaChild DevelopmentAnti-Inflammatory AgentsHumansFemaleMaleInfant, NewbornFollow-Up StudiesInfant, PrematureChild, PreschoolProspective StudiesChildTreatment Outcome

Substanzen

HydrocortisoneAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Stanford University School of Medicine, Palo Alto, California.
  • University of New Mexico Health Sciences Center, Albuquerque.
  • Women & Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Providence.
  • University of Texas at Austin, Dell Children's Hospital, Austin.

Förderung

  • NICHD NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

DeMauro, S. B., Kirpalani, H., Hintz, S., Watterberg, K. L., Watson, V., Lowe, J., Shankaran, S., Chawla, S., Vohr, B., Msall, M. E., D'Angio, C. T., Yoder, B. A., Lai, K., Winter, S., Colaizy, T. T., Merhar, S. L., Ziolkowski, K., Bann, C. M., Trotta, M., …, & Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (2026). Hydrocortisone in Preterm Infants and School-Age Functional Outcomes. JAMA Pediatrics, 180(2), 134. https://doi.org/10.1001/jamapediatrics.2025.4801

Vancouver

DeMauro SB, Kirpalani H, Hintz S, Watterberg KL, Watson V, Lowe J, et al. Hydrocortisone in Preterm Infants and School-Age Functional Outcomes. JAMA Pediatrics. 2026;180(2):134. doi:10.1001/jamapediatrics.2025.4801

BibTeX
@article{DeMauro2026,
  author = {DeMauro, Sara B and Kirpalani, Haresh and Hintz, Susan and Watterberg, Kristi L and Watson, Victoria and Lowe, Jean and Shankaran, Seetha and Chawla, Sanjay and Vohr, Betty and Msall, Michael E and D'Angio, Carl T and Yoder, Bradley A and Lai, Khanh and Winter, Sarah and Colaizy, Tarah T and Merhar, Stephanie L and Ziolkowski, Kristina and Bann, Carla M and Trotta, Marissa and Newman, Jamie E and Walsh, Michele C and Higgins, Rosemary D and Cahill, Tanya E and Duncan, Andrea F and Wilson-Costello, Deanne E and Peralta-Carcelen, Myriam and Arnold, Hope and Mosquera, Ricardo A and Heyne, Roy J and Fuller, Janell and McGowan, Elisabeth C and Cavanaugh, Brenna and Harmon, Heidi M and Maitre, Nathalie L and Neel, Mary Lauren and Van Meurs, Krisa P and Richards, Laurie A and Kilbride, Howard W and Hines, Abbey C and Natarajan, Girija and Trembath, Andrea and Benninger, Kristen L and Kesavan, Kalpashri and Malcolm, William F and Zanger, Dinorah and Reynolds, Ann Marie and Carlson, Martha and Das, Abhik and Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network},
  title = {Hydrocortisone in Preterm Infants and School-Age Functional Outcomes},
  journal = {JAMA Pediatrics},
  year = {2026},
  volume = {180},
  number = {2},
  pages = {134},
  doi = {10.1001/jamapediatrics.2025.4801}
}
Kostenlos starten →